Profile
Mr. Matthew J.
Clemmer, CFA MBA, is a Director & Senior Research Analyst at Ceredex Value Advisors LLC.
He is responsible for covering the healthcare sector.
Prior to joining Ceredex in 2025, Mr. Clemmer began his investment career in 2003, working as a Financial Advisor at MassMutual Financial Group & Wachovia Bank.
Over the years, he has held various positions, including Equity Research Associate at Deutsche Bank Securities, global equity analyst at Trilogy Global Advisors, and Emerging Equity Analyst at GW&K Investment Management.
Mr. Clemmer is a graduate of Eastern Mennonite University with a B.S.
in Business Administration.
He also holds an M.B.A. with a specialization in asset management from Boston College, Carroll Graduate School of Management.
He is a Chartered Financial Analyst (CFA) charterholder since 2012.
Matt Clemmer active positions
| Companies | Position | Start |
|---|---|---|
Ceredex Value Advisors LLC
Ceredex Value Advisors LLC Investment ManagersFinance Ceredex seeks to deliver excellent long-term investment performance by employing a well-crafted, methodical stock selection process with the dexterity to adapt to changing market conditions. Th firm offers value-equity strategies which are available in five portfolios: concentrated large-cap, large-cap, mid-cap smid-cap, and small-cap. The Ceredex strategies employ a traditional value style rooted in a fundamental, bottom-up approach. | Analyst-Equity | 01/03/2025 |
Former positions of Matt Clemmer
| Companies | Position | End |
|---|---|---|
GW&K Investment Management LLC
GW&K Investment Management LLC Investment ManagersFinance GW&K is a research-oriented adviser that primarily employs fundamental analysis for the evaluation of investment opportunities and the construction of investment portfolios. The firm specializes in Municipal Bond, Taxable Bond, Equity and Multi-Asset strategies. | Analyst-Equity | 01/01/2024 |
Trilogy Global Advisors LP
Trilogy Global Advisors LP Investment ManagersFinance Trilogy Global Advisors primarily provides discretionary portfolio management regarding US and non-US equity securities. The firm generally invests companies they believe show sustainable earnings power and are either traditional or early-stage growth companies. Trilogy offers the following portfolio strategies: Global Equity, Global Concentrated Equity, Global Select Equity, International Equity, International Small Cap Equity, Emerging Markets Equity and Emerging Wealth Equity. They may manage some portfolios following other equity, debt or balanced investment strategies, but generally do not actively offer these strategies on an on-going basis. Trilogy employs a multi-step quantitative stock screening process to assist in portfolio construction. They rely primarily on internally or externally generated models to construct investment portfolios. Trilogy also purchases and/or receives research data and software from third parties to support their research process. Trilogy’s Global Equity, Global Concentrated Equity, Global Select Equity, Emerging Wealth and International Equity strategies generally look for companies with more than $1 billion in market-cap and companies with a debt to equity ratio of greater than 75%, excluding financials. Trilogy’s International Small Cap Equity strategy generally eliminates companies with less than $300 million and greater than $4 billion in market-cap and companies with a debt to total capital ratio of greater than 60%. Trilogy’s Emerging Markets strategy conducts a separate screening process that generally eliminates companies with less than $750 million in market-cap and companies with a debt to total capital ratio of greater than 60% and looks for projected revenue growth. Companies that pass this screen are combined with emerging markets stocks from the Global strategy list. For the Emerging Wealth strategy, Trilogy's' global sector analysts generally identify developed market companies with more than 20% of revenues originating in emerging markets and/or a substantial part of earnings growth driven from emerging markets. Emerging market companies with material revenues from developed markets are generally eliminated unless research determines future growth will be driven by emerging markets. | Analyst-Equity | 01/02/2019 |
Training of Matt Clemmer
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
GW&K Investment Management LLC
GW&K Investment Management LLC Investment ManagersFinance GW&K is a research-oriented adviser that primarily employs fundamental analysis for the evaluation of investment opportunities and the construction of investment portfolios. The firm specializes in Municipal Bond, Taxable Bond, Equity and Multi-Asset strategies. | Finance |
Trilogy Global Advisors LP
Trilogy Global Advisors LP Investment ManagersFinance Trilogy Global Advisors primarily provides discretionary portfolio management regarding US and non-US equity securities. The firm generally invests companies they believe show sustainable earnings power and are either traditional or early-stage growth companies. Trilogy offers the following portfolio strategies: Global Equity, Global Concentrated Equity, Global Select Equity, International Equity, International Small Cap Equity, Emerging Markets Equity and Emerging Wealth Equity. They may manage some portfolios following other equity, debt or balanced investment strategies, but generally do not actively offer these strategies on an on-going basis. Trilogy employs a multi-step quantitative stock screening process to assist in portfolio construction. They rely primarily on internally or externally generated models to construct investment portfolios. Trilogy also purchases and/or receives research data and software from third parties to support their research process. Trilogy’s Global Equity, Global Concentrated Equity, Global Select Equity, Emerging Wealth and International Equity strategies generally look for companies with more than $1 billion in market-cap and companies with a debt to equity ratio of greater than 75%, excluding financials. Trilogy’s International Small Cap Equity strategy generally eliminates companies with less than $300 million and greater than $4 billion in market-cap and companies with a debt to total capital ratio of greater than 60%. Trilogy’s Emerging Markets strategy conducts a separate screening process that generally eliminates companies with less than $750 million in market-cap and companies with a debt to total capital ratio of greater than 60% and looks for projected revenue growth. Companies that pass this screen are combined with emerging markets stocks from the Global strategy list. For the Emerging Wealth strategy, Trilogy's' global sector analysts generally identify developed market companies with more than 20% of revenues originating in emerging markets and/or a substantial part of earnings growth driven from emerging markets. Emerging market companies with material revenues from developed markets are generally eliminated unless research determines future growth will be driven by emerging markets. | Finance |
Eastern Mennonite University
Eastern Mennonite University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wallace E Carroll School of Management
Wallace E Carroll School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ceredex Value Advisors LLC
Ceredex Value Advisors LLC Investment ManagersFinance Ceredex seeks to deliver excellent long-term investment performance by employing a well-crafted, methodical stock selection process with the dexterity to adapt to changing market conditions. Th firm offers value-equity strategies which are available in five portfolios: concentrated large-cap, large-cap, mid-cap smid-cap, and small-cap. The Ceredex strategies employ a traditional value style rooted in a fundamental, bottom-up approach. | Finance |
- Stock Market
- Insiders
- Matt Clemmer
















